Helicobacter pylori (H. pylori) infection has been suggested as a cause of impaired drug absorption. his infection leads to alteration of the gastric acid secretion that may change the conformational characteristics of drugs and their intestinal absorption leading to uncertainties about the dose to administer and the therapeutic results. A systematic review was undertaken to clarify the implications of drug absorption during the administration of replacement therapies. Methods: Electronic databases such as MEDLINE/Pubmed, EMBASE and he Cochrane Library [which includes Cochrane Database of Systematic Review (CDSR), the Cochrane Central Register of Controlled Trials (CENTRAL), the Database of Abstract of Reviews of Efect (DARE)] were searched. Grey literature databases (e.g. the International clinical trials registry platform, Trials Register, Clinical Trials.gov, Controlled Trials and TrialsCentral), heses database, Government publication and LILACS database were also searched. No language restriction was applied. Results: Infection and altered drug absorption were evaluated in patients under replacement therapies with iron, thyroxin and L-dopa. In all, seven studies included an improvement in drug absorption ater eradication and an existing inverse correlation between the grade of gastric inlammation and indices of drug absorption were noticed. Conclusion: his systematic review conirmed the presence of an interaction between infection and drug absorption of orally administered replacement therapies. Gastric acid reduction and subsequent alteration of drug composition seem to lead this mechanism. Clinicians should be aware of this possible interaction when starting a replacement therapy in patients and when evaluating poor clinical response.
INTRODUCTION
Since its discovery in 1982, interest in the role of Helicobacter pylori in determining human pathologies has grown and it has been recognised as one of the key factors responsible for many gastric and extra-gastric pathologies. Recently it has been also suggested as a causal agent of drug malabsorption. There is evidence that this infection is one of the principal determinants of altered gastric acid secretion whose severity depends on the extension of the infection in the stomach and on the duration of the disease [1] . Despite the fact that this infection can potentially alter the bioavailability of any drug, those who are part of a therapy designed to compensate for a lack or deiciency arising from inadequate nutrition, dysfunctions or losses (replacement therapies) are more likely to be afected by its presence and are potentially of high clinical interest due to the close relationship between the drug efect and the dose administered. herefore, the objective of this systematic review is to assess the efect of eradication on drugs absorption in patients undergoing oral replacement therapy.
Study inclusion and exclusion criteria
he participants considered were people over 16 years with H. pylori infection that had underwent replacement therapy independently from the histological grading of their infectionrelated gastric inlammation. hey were considered positive for H. pylori infection if at least one test of the following: histology, rapid urease test (RUT), culture, serology, urea breath test ( 13 C-UBT) and stool antigen test (SAT) was positive. If studies were a mixture of participants with impaired acid production due to H. pylori infection and other medical conditions (e.g. autoimmune atrophic gastritis or chronic proton pump inhibitor-PPI therapy), data regarding participants with the infection were extracted and analyzed separately. Oral replacement therapy was referred to any treatment orally administered to "compensate for a lack or deiciency arising from inadequate nutrition, from certain dysfunctions (glandular hyposecretion), or from losses (hemorrhage)" [2] whose efectiveness was evaluated in a routine clinical practice to inform a clinical decision (e.g. dosage to administer).
H. pylori eradication treatment was considered efective if administered for at least one week with an achieved eradication rate of at least 70%. Eradication status was considered valid if assessed from 4 to 6 weeks ater the end of the treatment by 13 C-UBT or SAT. Eleven randomized trials and observational studies (cohort studies, case-control and case-series) were included in the search to explore the impact of the intervention on the primary outcome in routine clinical practice. Meta-analyses and reviews were not included but their references were scanned to ind additional primary studies.
No language restrictions were used.
Selection procedure
Relevant studies were analyzed and extracted by two unblinded reviewers (G.F. and V.C.) using a form adapted from he Cochrane Data Extraction and Assessment Form [3] . Data collected included title, irst author, year of publication, type of publication (full text/ abstract, published/ unpublished), language, study design, characteristics of the population, disease/condition that needs replacement therapy, type of replacement therapy, type of H. pylori infection assessment, histological grading of gastric inlammation, if present, and assessment of hypochlorhydria, type of eradication treatment administered, type of outcome measurement performed, presence of adverse efects due to eradication therapy and drug absorption modiication. he quality of studies as Randomised Controlled Trials (RCTs), randomised cluster trials and randomised cross-over trials, non-randomised controlled trials (NRCTs) and controlled before-ater (CBA) studies was assessed by an adapted form of the Risk of Bias Criteria for EPOC reviews proposed by the Cochrane Public Health Group [4] . he quality of observational studies was assessed using an adaptation of the chart proposed by Petticrew et al. (2006) [5] . Diferences and disagreements were discussed and resolved by consensus.
RESULTS
he database searches were conducted in April 2014 and identified 3,400 potentially relevant findings. No further relevant records were identiied through the handsearch of abstracts and conferences. Ater duplicates had been removed, 3,109 out of 3,400 records were evaluated independently by two unblinded reviewers. A summary of the process is showed in a low diagram according to the PRISMA Statement [6] (Fig. 1) .
A total of seven studies were selected for review of the full paper and data extraction [7] [8] [9] [10] [11] [12] [13] . The high clinical heterogeneity detected in primary studies due to diferent types of intervention administered, diferent outcomes described and the low number of identiied studies did not allow us to pool data together to produce a summary measure and to perform statistical evaluation. However, the systematic approach that was used made it possible to evaluate the efect of the intervention between studies on the same replacement therapy and to speculate about the presence of a common pattern among studies on diferent drugs [14] . Characteristics of the included studies are shown in Table I .
H. pylori eradication and thyroxine
Two studies explored the efect of H. pylori eradication therapy on thyroxine absorption by looking at thyroid function test commonly used to check the efect of thyroxine replacement therapy. hey both performed thyroid function tests before and after the administration of eradication treatment and noticed a statistically signiicant improvement in the results. In particular, in the study by Centanni et al. [7] , the daily need for thyroxine was nearly reversed ater eradication treatment and was associated with a decrease in thyrotropin levels that was calculated to be near 94% [15] . Similar results were obtained by Bugdaci et al. (2011) [12] , who noticed a statistically signiicant improvement in thyroid function tests ater H. pylori eradication in all of the enrolled cases. hey also noticed the development of a clinical condition related to an excessive absorption of thyroxine (thyrotoxicosis) in 21% of cases ater the cure of the infection.
H. pylori eradication and L-Dopa absorption
Two studies evaluated the efect of H. pylori eradication treatment on L-dopa absorption [9, 10] . he efect of the treatment was evaluated on the pharmacokinetic and clinical response to L-dopa in patients with advanced Parkinson's disease and H. pylori infection.
he irst study was a case series of six patients where the authors demonstrated that the eradication treatment led to a 21% increase in L-dopa plasma concentration and a concomitant clinical beneit. hey subsequently conirmed their results in a RCT where patients were randomly divided in two groups and received either eradication therapy or placebo. In this study, the eradication therapy group achieved a 54% increase in L-dopa absorption and showed signiicant symptom improvement. his positive relationship was reinforced by the absence of L-dopa pharmacokinetics and symptoms improvement in two patients that failed the eradication.
H. pylori eradication and iron absorption
All studies that explored the efect of H. pylori eradication on iron absorption concluded that H. pylori infection is associated with a poorer response to oral iron therapy, that its treatment can enhance the eicacy of oral iron replacement therapy and that the screening for this infection should be considered in patients with unexplained or refractory iron deiciency anemia [4, 8, 16] . Results of the case series performed by Kotb et al. (2012) [13] showed a statistically signiicant increase in haematological indices such as haemoglobin (Hb), serum ferritin (SF) and transferrin saturation (TF) achieved ater H. pylori eradication compared to baseline at 6 and 12 weeks post therapy. hey also noticed a signiicant inverse correlation with the above mentioned parameters and the grade of inlammation detected in the stomach. heir results were supported by the indings of two randomised trials [8, 11] that explored also changes in iron related parameters in blood ater H. pylori eradication. All three studies considered a slightly diferent panel of iron related parameters other than haemoglobin, which was a shared surrogate outcome for the evaluation of the efectiveness of iron replacement therapy. Hemoglobin values signiicantly increased ater eradication in all the studies.
Quality assessment of included studies he quality of included studies was assessed independently by two unblinded reviewers (G.F. and V.C.) and diferences were discussed and solved by consensus. Each study was labelled at a "Low, "Medium" or "High" risk of bias taking into account the study design and the potential impact of the identiied bias. An adapted form of the Risk of Bias Criteria for EPOC reviews proposed by the Cochrane Public Health Group (CPHG, 2011) was used for RCTs and NRCTs, while the quality of Observational Studies was assessed using an adaptation of the chart proposed by Petticrew et al. [5] .
Based on the results of the assessment performed, case series on the relationship between H. pylori eradication and thyroxine absorption [7, 12] were considered of medium quality. he two studies performed by Pierantozzi et al. [9, 10] on L-dopa absorption ater H. pylori treated infection were a case series and a randomised trial and were considered of low and high quality, respectively. Finally, studies on H. pylori eradication and iron absorption were evaluated as being of low quality [8, 11] and medium quality [13] , respectively.
DISCUSSION
his systematic review provides strength to the hypothesis that there is an inverse relationship between H. pylori infection and drug absorption. Although this link has been previously evaluated [13] , this review focused on a particular category of drugs which are frequently used in routine clinical practice and whose dosage and clinical efectiveness strictly depends on the amount of drug absorbed; with appropriate restrictions and speciications they have been referred to as "replacement therapies" because they are used to compensate for a lack or deiciency arising from inadequate nutrition, dysfunctions or losses. It has been noticed that, independently from the drug considered, there is a positive modiication in replacement therapies absorption ater H. pylori eradication [17] . his modiication can be seen both directly by using pharmacokinetics indices (AUC and Cmax) and/or indirectly through the modiication of speciic parameters in blood tests or through clinical scores.
hose indings suggested a possible mechanism that relates the infection and drug absorption based on alterations in gastric acidity. Previous studies have reported that the intestinal absorption of thyroxine, L-Dopa and iron are pH-dependent [7, 18, 19] . However, only two studies on thyroxine absorption [7, 12] and one study on iron absorption [13] explored the correlation between the grade of H. pylori related gastritis in gastric biopsies, its location in the stomach mucosa (e.g. antrum or corpus), the gastric pH and drug absorption with pre and post eradication changes. Hypochloridria is not the only possible explanation of impaired drug absorption in H. pylori positive patients. Past studies on L-dopa showed that H. pylori infection can cause a delayed gastric emptying. his may be responsible for modiications in the normal pathway of drug absorption by favouring a bacterial overgrowth that can compete with absorption mechanisms and by increasing the contact time between a substance and gastric enzymes [20] . Alternatively, for iron it has been speculated that H. pylori can actively compete with the body for its absorption [21] . Iron also needs to be transformed into an absorbable form and this is achieved both by the presence of an appropriate gastric pH and by the presence of ascorbic acid secreted in gastric juice.
H pylori infection alters both mechanisms [22] . Chronic blood loss related to H. pylori gastritis can be another reasonable cause of iron depletion and poor response to orally administered replacement therapy. However, not all patients with H. pylori gastritis develop iron deiciency anemia, suggesting that more than one mechanism can be involved [23] .
From these indings it is clear that drugs absorption is a complex mechanism that still needs to be fully understood. his review provided strength to the hypothesis that H. pylori infection plays an important role in drug metabolism and that it is one of the leading cause in altering the mechanisms of drug absorption.
he implications of impaired drug absorption in subjects with H. pylori infection can be relevant for clinical practice due to the high prevalence of the infection worldwide [24] . At the same time, clinical conditions that need replacement therapies, such as hypothyroidism, iron deiciency anemia and Parkinson's disease, are widespread. It has been estimated that about 4.6% of the United States population has hypothyroidism, increasing with age to more than 10% in adults above 65 years old [15, 16] . Iron deiciency anemia is even more prevalent, with 30% of the world population afected [26] . Finally, an estimated seven to ten million people worldwide are living with Parkinson's disease [27] .
he presence of a relationship between drug absorption and H. pylori raises further questions regarding the opportunity to change our clinical practice. Ideally, patients that need to start a replacement therapy as well as patients currently under therapy should be screened for H. pylori infection. Moreover, the dosage of the administered drugs should be re-evaluated, with a diferent timing in patients that have been eradicated to avoid overdose and related side efects.
What diferentiates this infection from other causes of impaired drug absorption is that alterations related to the presence of H. pylori are reversible once the bacteria is eradicated with an antibacterial therapy [28] . However, the administration of an eradication treatment for every person diagnosed with H. pylori infection will cost more than $32 billion in the Unites States alone [29] . his underlines that a clear strategy is required to target appropriately people that would beneit from the eradication treatment. his review can contribute to this aim by highlighting speciic clinical conditions that improve ater H. pylori eradication and by targeting subgroups of patients that need to be screened for H. pylori positivity before being administered replacement therapies.
Despite the fact that results on the relationship between H. pylori and drug absorption that have been obtained in this review are consistent, there are several limitations that need to be highlighted: the paucity of studies available for inclusion, the limitations of the available data and the methodological weaknesses that have been evaluated. hese determine the need to consider these results as non-deinitive. Moreover, the statistical signiicance of the results could not fully correspond to a clinical signiicance that needs to be further explored with better quality studies.
CONCLUSIONS
This systematic review has found a small number of studies that support the hypothesis of an existing interaction between H. pylori infection and drug absorption of orally administered replacement therapies. Clinicians should be aware of this possible interaction when initiating a replacement therapy in a new patient and when evaluating poor clinical or laboratory response in patients under chronic treatments. he optimization of the medical therapy to obtain the best result with the lowest number of side efects should be the goal of any correct therapeutic approach. However, the limitations that have been highlighted and the scarcity of good quality studies on this topic underline the necessity of a greater number of studies on this subject and of better quality.
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